Virtual

Join us for an expert-led session exploring the rising concern of measles outbreaks and their unique risks for patients undergoing Hematopoietic Cell Transplantation (HCT) and CAR T-cell therapies.

Join ASTCT Director of Government Relations, Alycia Maloney, JD, and the reimbursement and policy advisors to ASTCT from Nimitt Consulting, for the Medicare FY 2026 IPPS Proposed Rule webinar.r on May 15 at 12 p.m. CDT.

Join us for this overview of recent developments in cord blood transplant for heme malignancies. Our focus will be on manipulated graft sources and insights from real world use of expanded cord blood.

During the webinar, Drs. White and Nezalova-Henriksen will present two articles related to: (a) Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic HSCT for older patients with AML or MDS and (b) Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients.